Abstract: The invention describes compositions that include a stevia sweetener and a salt of a steviol glycoside, wherein the concentration of the components provide an improved taste profile where bitterness, after taste and/or lingering of the stevia sweetener is decreased or eliminated.

Abstract: Disclosed are ester compounds of the formulae wherein Rc is alkylene, arylene, arylalkylene, or alkylarylene as further defined herein, Rd is alkylene, arylene, arylalkylene, or alkylarylene as further defined herein, and m and n are integers representing the numbers of repeat monomer units. The materials are suitable for use in inks and other applications.

Abstract: Analogs of 3-O-acetyl-11-keto-beta-boswellic acid and their method of preparation are presented. The analogs may be used as anti-inflammatory and anti-cancer agents. The compounds inhibit 5-lipoxygenase enzyme and various cell lines related to inflammation as well as to cancer showing a significantly better efficacy when compared to the normal boswellic acids. The analogs are capable of controlling and treating various inflammatory diseases and cancers.

Abstract: The present invention is correlated with a derivative of 18?-glycyrrhetinic acid apt to suppressing cancer cells, which is selected from a group comprising of structure I and structure II: wherein residue R1 is selected from one of CH3 and CH2C6H5, residue R2 is selected from one of COOCH3, COOCH2CH3, COOCH(CH3)2, CONHCH2CH3, CONHCH2CH2CH3, and CONHCH2(CH3)2, and residue R3 is selected from one of COOCH2CH3, COOCH(CH3)2, CONHCH2CH3, CONHCH2CH2CH3, and CONHCH2(CH3)2.

Abstract: This invention provides methods, processes, compounds and compositions for modulating the gene expression or secretion of adhesion proteins, angiopoietins or their receptors to cure diseases, for anti-angiogenesis and for treating parasites, wherein the adhesion proteins or receptors comprise fibronectin, integrins family, myosin, vitronectin, collagen, laminin, glycosylation cell surface proteins, polyglycans, cadherin, heparin, tenascin, CD 54, CAM, elastin and FAK; wherein the angiopoietins comprise angiopoietin 1, angiopoietin 2, angiopoietin 3, angiopoietin 4, angiopoietin 5, angiopoietin 6, angiopoietin 7, angiopoietin-like 1, angiopoietin-like 2, angiopoietin-like 3, angiopoietin-like 4, angiopoietin-like 5, angiopoietin-like 6, and angiopoietin-like 7; wherein the cancers comprise breast cancer, leukocyte cancer, liver cancer, ovarian cancer, bladder cancer, prostate cancer, skin cancer, bone cancer, brain cancer, leukemia cancer, lung cancer, colon cancer, CNS cancer, melanoma cancer, renal cancer, c

Abstract: In one aspect, the invention relates methods for inhibiting or preventing muscle atrophy or increasing muscle mass by providing to a subject in need thereof an effective amount of ursolic acid, a derivative thereof, or an analog of the ursane scaffold. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, modified C-3 betulinic acid and other structurally related natural products derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors. These compounds are useful for the treatment of HIV and AIDS.

Abstract: Compounds according to Formula (I) are described along with compositions containing the same and methods of use thereof for the treatment of viral infections.

Abstract: The present invention concerns novel pharmaceutically active triterpene derivatives, pharmaceutical compositions containing the same, their use as medicaments, and the use of the compounds for the manufacture of specific medicaments. The present invention also concerns a method of treatment involving administration of the compounds. Specifically, the compounds are derivatives of betulinic acid having substitutions at one or more of the C-3, C2-8 and C-19 positions as further described herein. The novel compounds are useful as antiretroviral agents. In particular, the novel compounds are useful for the treatment of Human Immunodeficiency Virus (HIV).

Abstract: The invention relates to compounds derived from betulin, and to the use thereof in plant pest control, particularly as antifeedants for butterfly larvae, beetles and snails. Further, the invention relates to novel betulin derivatives and methods for the production thereof either directly from betulin, or via intermediates derived therefrom.

Abstract: Several ursolic acid derivatives and pharmaceutical compositions thereof are provided. The ursolic acid derivatives and the pharmaceutical compositions thereof have at least one of an anticancer and an anti-inflammatory effects. A method for increasing a reactive oxygen species in a cell is also provided. The method comprises a step of providing the cell with a pharmaceutical composition including an ursolic acid derivative.

Abstract: The invention relates to 17? lupane derivatives of formula (I): wherein R1 and X are as defined herein, and pharmaceutically acceptable salts and solvates thereof. These compounds exhibit significant anti-HIV activity. Thus, the invention also relates to methods for prevention or treatment of HIV infection by administering therapeutically effective amounts of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof to a subject in need of such treatment.

Abstract: This invention relates to novel AKBA analogs of the formula I given below: Where in R1, R2, R3, R4 and R5 in each of the said analogs are: 1. R1?OCHO, R2?H, R3?COOH, R4 & R5?O 2. R1?OCOCH2Cl, R2?H, R3?COOH, R4 & R5?O 3. R1?5?-O-methylgalloyloxy, R2?H, R3?COOH, R4 & R5?O 4. R1?OCOCH2CH2COOH, R2?H, R3?COOH, R4 & R5?O 5. R1?8?,9?-Dihydro-4?-hydroxycinnamoyloxy, R2?H, R3?COOH, R4 & R5?O 6. R1?4?-Hydroxycinnamoyloxy, R2?H, R3?COOH, R4 & R5?O 7. R1?3?,4?-Dimethoxycinnamoyloxy, R2?H, R3?COOH, R4 & R5?O 8. R1?3?,4?-Dihydroxy-5?-methoxycinnamoyloxy, R2?H, R3?COOH, R4 & R5?O 9. R1?OCOCH2NH(tert-BOC), R2?H, R3?COOCH3, R4 & R5?O 10. R1?OCOCH2NH2HCl, R2?H, R3—COOH, R4 & R5?O 11. R1?OCOCH(CH3)NH2HCl, R2?H, R3?COOH, R4 & R5?O 12. R1?H, R2?OH, R3?COOCH3, R4 & R5?O 13. R1?H, R2?Br, R3 COOCH3, R4 & R5?O 14. R1?CN, R2?H, R3?COOCH3, R4 & R5?O 15. R1?SH, R2?H, R3?COOCH3, R4& R5?O 16. R1 & R2?N(OH), R3?COOCH3, R4 & R5?O 17.

Abstract: A positive type resist composition for forming a high resolution resist pattern and a method of forming a resist pattern are provided which use a low-molecular-weight material as a base component, and a compound and a dissolution inhibitor that are each suitable for the positive type resist composition. Here, the compound is a non-polymer having a molecular weight of 500 to 3000, and is decomposed under the action of an acid to produce two or more molecules of a decomposition product having a molecular weight of 200 or more; the dissolution inhibitor comprises the compound; the positive type resist composition comprises the compound and the acid generator component; and the method of forming a resist pattern uses the positive type resist composition.

Abstract: This invention is directed to a novel pharmacological property of ?-Amyrin acetate derived from Tabernaemontana dichotoma as a potent ?-glycosidase inhibitor, which has not been reported before. The present discovery also provides for the use of this compound as a new oral hypoglycemic drug in the treatment of type II diabetes being approximately 35 times potent compared with Acarbose, a standard drug widely prescribed to type II diabetes patients.

Abstract: A tetrahydronaphthalene derivative represented by the general formula (I) and a liquid crystal composition containing the same. A compound represented by the general formula (I) shows superior liquid crystallinity and co-solubility with conventional liquid crystal compounds and compositions. Furthermore, addition of such a compound enables the threshold voltage to be significantly reduced with almost no deleterious effect on the responsiveness. In addition, a compound of the present invention can also be easily produced industrially, is colorless, and is chemically stable. Consequently, liquid crystal compositions containing such a compound are extremely useful as liquid crystals, and are particularly suitable for liquid crystal displays requiring a wide operating temperature range, low voltage driving and a high response speed.

Abstract: A compound of formula (I): 1

Abstract: The present invention relates to a method of catalyzing etherification, esterification, hydration, ether cleavage, isomerization alkylation, or other reactions which are catalyzable with an acid or molecular sieve catalyst. Said reactions are conducted using a novel, dual functional catalyst prepared with active components and a small amount of binder, wherein said dual functional catalyst comprises cylindrical pellets which are molded such that a cross-section or each pellet has a window lattice shape with external teeth, or a star shape with inner spokes.

Abstract: Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. The amphiphiles contain lipophilic groups derived from steroids, from mono or dialkylamines, or from ether or ester-linked alkyl groups, and cationic groups, protonatable at physiological pH, derived from amines, alkylamines or polyalkylamines. There are provided also therapeutic compositions prepared typically by contacting a dispersion of one or more cationic amphiphiles with the therapeutic molecules. Therapeutic molecules that can be delivered into cells according to the practice of the invention include DNA, RNA, and polypeptides. Representative uses of the therapeutic compositions of the invention include providing gene therapy, and delivery of antisense polynucleotides or biologically active polypeptides to cells. With respect to therapeutic compositions for gene therapy, the DNA is provided typically in the form of a plasmid for complexing with the cationic amphiphile.

Abstract: This invention relates to novel 4-(3,4-dioxocyclobuten-1-yl)chromenes and dihydronaphthalenones and 3-(3,4-dioxocyclobuten-1-yl)indenes and salts thereof having smooth muscle relaxing activity, to their use in the treatment of hypertension as well as for treatment of peripheral vascular disease, congestive heart failure, disorders involving excessive smooth muscle contraction of the urinary tract such as incontinence or of the gastrointestinal tract such as irritable bowel syndrome, asthma, and hair loss and to pharmaceutical compositions containing an invention compound. The present invention discloses compounds represented by the formula (I): ##STR1## wherein: R.sub.1 and R.sub.2, independent from each other, are selected from the following: C.sub.1-6 perfluoroalkoxy, C.sub.1-6 perfluoroalkyl, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, hydroxyl, C.sub.1-6 alkoxycarbonyl, nitro, cyano, halogen, C.sub.1-6 alkylsulfonamido, C.sub.1-6 perfluoroalkylsulfonamido, amino, C.sub.1-6 acylamino, C.sub.

Abstract: Presented are a glycyrrhetic acid derivative of the following formula ##STR1## or a pharmacologically acceptable salt thereof, which has antioxidant, antiinflammatory and/or antiallergic activity, a process for producing said compound or salt, and an antioxidant, antiinflammatory and/or antiallergic composition comprising said compound or salt.

Abstract: The present invention relates to compounds of formula (I)ArCH.sub.2 R.sup.1 (I)or a monomethyl or monoethyl ether thereof (the compound of formula (I) including these ethers may contain no more than 30 carbon atoms in total); ethers, esters, thereof; acid addition salts thereof; wherein Ar is a C.sub.15-18 fused tetracarbocyclic ring system containing 3 or 4 aromatic rings or a C.sub.17-22 fused pentacarbocyclic ring system containing 4, or 5 aromatic rings, or a substituted derivative thereof; the ring system Ar should be planar or deviate only slightly from planarity. Thus, the ring system contains a maximum of two non-aromatic carbon atoms which may be in the same ring, in which case they are adjacent, or in different rings;Ar is not perylene, fluoranthene, chrysene, pyrene, or triphenylene;R.sup.1 contains not more than eight carbon atoms and is a group ##STR1## wherein m is 0 or 1;R.sup.5 is hydrogen;R.sup.6 and R.sup.7 are the same or different and each is hydrogen or C.sub.

Abstract: The present invention relates to compounds of formula (I)ArCH.sub.2 R.sup.1 (I)or a monomethyl or monoethyl ether thereof (the compound of formula (I) including these ethers may contain no more than 30 carbon atoms in total); ethers, esters, thereof; acid addition salts thereof; wherein Ar is a C.sub.15-18 fused tetracarbocyclic ring system containing 3 or 4 aromatic rings or a C.sub.17-22 fused pentacarbocyclic ring system containing 4, or 5 aromatic rings, or a substituted derivative thereof; the ring system Ar should be planar or deviate only slightly from planarity. Thus, the ring system contains a maximum of two non-aromatic carbon atoms which may be in the same ring, in which case they are adjacent, or in different rings;Ar is not perylene, fluoranthene, chrysene, pyrene, or triphenylene;R.sup.1 contains not more than eight carbon atoms and is a group ##STR1## wherein m is 0 or 1; R.sup.5 is hydrogen;R.sup.6 and R.sup.7 are the same or different and each is hydrogen or C.sub.

Abstract: Analogs of the glycoside stevioside are disclosed. These materials have the formula ##STR1## wherein R.sub.1 and R.sub.2 are as follows:______________________________________ R.sub.1 R.sub.2 ______________________________________ (CH.sub.2).sub.3 SO.sub.3.sup.- M.sup.+ .beta.-D-Sophorose (CH.sub.2).sub.3 SO.sub.3.sup.- M.sup.+ (CH.sub.2).sub.3 SO.sub.3.sup.- M.sup.+ H (CH.sub.2).sub.3 SO.sub.3.sup.- M.sup.+ ______________________________________and M.sup.+ is a physiologically acceptable alkali metal cation.

Abstract: The invention is directed to 3-oxo-D-homosteroids and derivatives thereof which are useful as antiantigens.

Abstract: Analogs of the glycoside stevioside are disclosed. These materials have the formula ##STR1## wherein R.sub.1 and R.sub.2 are as follows:______________________________________ R.sub.1 R.sub.2 ______________________________________ --(CH.sub.2).sub.3 SO.sub.3.sup.- M.sup.+ .beta.-D--Sophorose --(CH.sub.2).sub.3 SO.sub.3.sup.- M.sup.+ --(CH.sub.2).sub.3 SO.sub.3.sup.- M.sup.+ --H --(CH.sub.2).sub.3 SO.sub. 3.sup.- M.sup.+ ______________________________________and M.sup.+ is a physiologically acceptable alkali metal cation.

Abstract: The present invention is directed to 3-oxo, 6,9-hydro or halo, 11-oxo or (.alpha.--H,.beta.--OH), 17a-alkanoyloxy, 17a.beta.-carboxylate D-homosteroids which are useful as antiinflammatory agents.

Abstract: Novel modified rosin esters and a method of preparing these novel compounds are described. The novel compounds are useful in surfactant compositions.

Abstract: The present disclosure is concerned with 17a-(m-iodobenzoyloxy) substituted D-homosteroids and a process for their manufacture. The compounds are useful as intermediates and also as hormonal agents, particularly progestational agents.

Abstract: Pharmaceutically active compounds of the formula ##STR1## wherein --OR.sub.1, --OR.sub.2, --OR.sub.3 and --OR.sub.4, which may be the same or different, each represents a free or esterified hydroxyl group and --COOR.sub.5 represents a free or esterified carboxyl group, are provided together with processes for their production and pharmaceutical compositions containing them. Compounds of formula II and III possess valuable cicatrizing and anti-inflammatory properties.

Abstract: The present invention provides new glycyrrhetinic acid derivatives of the general formula: ##STR1## wherein R is an alkylene or cycloalkylene radical and X represents an oxygen atom or two hydrogen atoms; and the non-toxic salts and esters thereof.